• Molecular NameTrilostane
  • Synonymtrilostane
  • Weight329.44
  • Drugbank_IDDB01108
  • ACS_NO13647-35-3
  • Show 2D model
  • LogP (experiment)2.0
  • LogP (predicted, AB/LogP v2.0)2.12
  • pkaN/A
  • LogD (pH=7, predicted)1.12
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.39
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors2
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA86.01
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life8 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include darkening of skin, drowsiness or tiredness, loss of appetite, mental depression, skin rash, and/or vomiting.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A